Analyst Research

Report Title Price
Provider: Wright Reports
$75.00
Provider: Stock Traders Daily
$20.00
Provider: Reuters Investment Profile
$20.00
Provider: TheStreet.com Ratings
$10.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Kamada Ltd Completion of Pivotal Phase II/III Clinical Trial


Wednesday, 11 Dec 2013 08:49am EST 

Kamada Ltd:Says it has completion of the pivotal Phase II/III clinical trial in Europe and Canada of the company's inhaled Alpha-1 Antitrypsin (AAT) therapy for the treatment of Alpha-1 Antitrypsin Deficiency (AATD or Inherited Emphysema).Kamada expects to report top-line results from this study in the first quarter of 2014. 

Company Quote

1184.0
-18.0 -1.50%
27 Nov 2014